Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie för att undersöka effektiviteten och säkerheten av anifrolumab hos vuxna med kronisk och/eller subakut kutan lupus erythematosus (LAVENDER)

10 november 2026 uppdaterad av: AstraZeneca

En multicenter, randomiserad, dubbelblind, placebokontrollerad, fas III-studie för att utvärdera effektiviteten och säkerheten av anifrolumab hos vuxna med kronisk och/eller subakut kutan lupus erythematosus som är refraktär och/eller intolerant mot malariabehandling

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).

Studieöversikt

Status

Aktiv, inte rekryterande

Detaljerad beskrivning

This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.

Studietyp

Interventionell

Inskrivning (Faktisk)

339

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Ciudad de Buenos Aires, Argentina, 1221
        • Research Site
      • Córdoba, Argentina, 5000
        • Research Site
      • Córdoba, Argentina, X5004BAL
        • Research Site
      • Quilmes, Argentina, 1878
        • Research Site
      • San Miguel, Argentina, 1663
        • Research Site
      • Kogarah, Australien, 3168
        • Research Site
      • Melbourne, Australien, 3004
        • Research Site
      • Mitcham, Australien, 3132
        • Research Site
      • Westmead, Australien, 2145
        • Research Site
      • Woolloongabba, Australien, 04102
        • Research Site
      • Belo Horizonte, Brasilien, 30150-221
        • Research Site
      • Porto Alegre, Brasilien, 90035903
        • Research Site
      • Rio de Janeiro, Brasilien, 22470-220
        • Research Site
      • Salvador, Brasilien, 40150-150
        • Research Site
      • São Paulo, Brasilien, 05403-000
        • Research Site
      • Sofia, Bulgarien, 1784
        • Research Site
      • Sofia, Bulgarien, 1463
        • Research Site
      • Sofia, Bulgarien, 1528
        • Research Site
      • Osorno, Chile, 200025
        • Research Site
      • Santiago, Chile, 7500571
        • Research Site
      • Santiago, Chile, 130021
        • Research Site
      • Barranquilla, Colombia, 080020
        • Research Site
      • Bogotá, Colombia, 110221
        • Research Site
      • Aarhus, Danmark, 641-8510
        • Research Site
      • Copenhagen, Danmark, 2100
        • Research Site
      • Iloilo City, Filippinerna, 5000
        • Research Site
      • Lipa, Filippinerna, 4217
        • Research Site
      • Manila, Filippinerna, 1000
        • Research Site
      • Bois-Guillaume, Frankrike, 76031
        • Research Site
      • Dijon, Frankrike, 21000
        • Research Site
      • Lyon, Frankrike, 69437
        • Research Site
      • Montivilliers, Frankrike, 76290
        • Research Site
      • Nantes, Frankrike, 44000
        • Research Site
      • Paris, Frankrike, 75010
        • Research Site
      • Paris, Frankrike, 75014
        • Research Site
      • Paris, Frankrike, 75013
        • Research Site
      • Paris, Frankrike, 75970
        • Research Site
      • Poitiers, Frankrike, 86000, FR
        • Research Site
      • Toulouse, Frankrike, 31059
        • Research Site
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85028
        • Research Site
    • California
      • Covina, California, Förenta staterna, 91722
        • Research Site
      • La Jolla, California, Förenta staterna, 92037
        • Research Site
      • Los Angeles, California, Förenta staterna, 90045
        • Research Site
      • Los Angeles, California, Förenta staterna, 90089
        • Research Site
      • Orange, California, Förenta staterna, 92868
        • Research Site
      • San Francisco, California, Förenta staterna, 94143
        • Research Site
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80045
        • Research Site
    • Connecticut
      • New Haven, Connecticut, Förenta staterna, 06519
        • Research Site
    • District of Columbia
      • Washington D.C., District of Columbia, Förenta staterna, 20037
        • Research Site
    • Florida
      • Fort Lauderdale, Florida, Förenta staterna, 33309
        • Research Site
      • Miami, Florida, Förenta staterna, 33174
        • Research Site
      • Plantation, Florida, Förenta staterna, 33324
        • Research Site
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60637
        • Research Site
      • Chicago, Illinois, Förenta staterna, 60611
        • Research Site
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Research Site
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02114
        • Research Site
      • Boston, Massachusetts, Förenta staterna, 02115-5817
        • Research Site
    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48109
        • Research Site
      • Bloomfield Hills, Michigan, Förenta staterna, 48302
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Förenta staterna, 55905
        • Research Site
    • Nebraska
      • Omaha, Nebraska, Förenta staterna, 68198-5885
        • Research Site
    • New York
      • New York, New York, Förenta staterna, 10028
        • Research Site
      • Rochester, New York, Förenta staterna, 14642
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28207
        • Research Site
      • Statesville, North Carolina, Förenta staterna, 28625
        • Research Site
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44195
        • Research Site
    • Oregon
      • Portland, Oregon, Förenta staterna, 97239
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02903
        • Research Site
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Research Site
    • Texas
      • Dallas, Texas, Förenta staterna, 75390-8843
        • Research Site
    • Virginia
      • Charlottesville, Virginia, Förenta staterna, 22903
        • Research Site
      • Roanoke, Virginia, Förenta staterna, 24016
        • Research Site
      • Athens, Grekland, 12462
        • Research Site
      • Athens, Grekland, 16121
        • Research Site
      • Brescia, Italien, 25123
        • Research Site
      • Cona, Italien, 44124
        • Research Site
      • Florence, Italien, 50121
        • Research Site
      • Milan, Italien, 20132
        • Research Site
      • Naples, Italien, 80138
        • Research Site
      • Reggio Emilia, Italien, 42123
        • Research Site
      • Roma, Italien, 00144
        • Research Site
      • Rome, Italien, 00168
        • Research Site
      • Chūōku, Japan, 104-8560
        • Research Site
      • Fukuoka, Japan, 812-8582
        • Research Site
      • Kanazawa, Japan, 920-8641
        • Research Site
      • Kita-gun, Japan, 761-0793
        • Research Site
      • Nagoya, Japan, 457-8510
        • Research Site
      • Nagoya, Japan, 467-8602
        • Research Site
      • Wakayama, Japan, 641-8510
        • Research Site
      • Yokohama, Japan, 232-0024
        • Research Site
      • tabashi City, Japan, 173-8606
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Research Site
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • Research Site
      • Toronto, Ontario, Kanada, M5T 2S8
        • Research Site
      • Changchun, Kina, 130021
        • Research Site
      • Changsha, Kina, 410011
        • Research Site
      • Chengdu, Kina, 610021
        • Research Site
      • Chongqing, Kina, 400016
        • Research Site
      • Dongguan, Kina, 523059
        • Research Site
      • Guangzhou, Kina, 510120
        • Research Site
      • Heilongjiang, Kina, 150086
        • Research Site
      • Jinan, Kina, 250022
        • Research Site
      • Shanghai, Kina, 200025
        • Research Site
      • Shanghai, Kina, 200443
        • Research Site
      • Shenzhen, Kina, 518053
        • Research Site
      • Shenzhen, Kina, 518020
        • Research Site
      • Shenzhen, Kina, 518052
        • Research Site
      • Zhuzhou, Kina, 412007
        • Research Site
      • Ürümqi, Kina, CN-830004
        • Research Site
      • Guadalajara, Mexiko, 44340
        • Research Site
      • Guadalajara, Mexiko, 44610
        • Research Site
      • Mexico City, Mexiko, 07760
        • Research Site
      • Veracruz, Mexiko, 91910
        • Research Site
      • Breda, Nederländerna, 4818 CK
        • Research Site
      • Rotterdam, Nederländerna, 3015 GD
        • Research Site
      • Papatoetoe, Nya Zeeland, 2025
        • Research Site
      • Katowice, Polen, 40-851
        • Research Site
      • Kielce, Polen, 25-316
        • Research Site
      • Ossy, Polen, 40-027
        • Research Site
      • Rzeszów, Polen, 35-055
        • Research Site
      • Warsaw, Polen, 02-637
        • Research Site
      • Braga, Portugal, 4710-243
        • Research Site
      • Lisbon, Portugal, 1649-035
        • Research Site
      • Porto, Portugal, 4099-001
        • Research Site
      • Bucharest, Rumänien, 020125
        • Research Site
      • Iași, Rumänien, 700291
        • Research Site
      • Belgrade, Serbien, 11000
        • Research Site
      • Kragujevac, Serbien, 34000
        • Research Site
      • Košice, Slovakien, 04001
        • Research Site
      • Piešťany, Slovakien, 92101
        • Research Site
      • Barcelona, Spanien, 8035
        • Research Site
      • Barcelona, Spanien, 08025
        • Research Site
      • Castellon, Spanien, 12004
        • Research Site
      • Granada, Spanien, 18012
        • Research Site
      • L'Hospitalet de Llobregat, Spanien, 08907
        • Research Site
      • Las Palmas de Gran Canaria, Spanien, 35010
        • Research Site
      • Madrid, Spanien, 28034
        • Research Site
      • Madrid, Spanien, 28041
        • Research Site
      • Madrid, Spanien, 28040
        • Research Site
      • Madrid, Spanien, 28006
        • Research Site
      • Majadahonda, Spanien, 28222
        • Research Site
      • Salamanca, Spanien, 37007
        • Research Site
      • Seville, Spanien, 41014
        • Research Site
      • Valencia, Spanien, 46014
        • Research Site
      • Valencia, Spanien, 46017
        • Research Site
      • Vigo, Spanien, 36200
        • Research Site
      • Cambridge, Storbritannien, CB2 0QQ
        • Research Site
      • Leeds, Storbritannien, LS2 9JT
        • Research Site
      • London, Storbritannien, NW1 2PG
        • Research Site
      • London, Storbritannien, SE5 9RS
        • Research Site
      • London, Storbritannien, SE1 7EH
        • Research Site
      • London, Storbritannien, NW3 2QG
        • Research Site
      • Newcastle upon Tyne, Storbritannien, NE1 4LP
        • Research Site
      • Cape Town, Sydafrika, 7500
        • Research Site
      • Johannesburg, Sydafrika, 2193
        • Research Site
      • Seoul, Sydkorea, 03080
        • Research Site
      • Seoul, Sydkorea, 06591
        • Research Site
      • Seoul, Sydkorea, 06973
        • Research Site
      • Kaohsiung City, Taiwan, 83301
        • Research Site
      • Taichung, Taiwan, 404
        • Research Site
      • Taipei, Taiwan, 10449
        • Research Site
      • Bangkok, Thailand, 10330
        • Research Site
      • Bangkok, Thailand, 10700
        • Research Site
      • Hat Yai, Thailand, 90110
        • Research Site
      • Khlong Luang, Thailand, 12120
        • Research Site
      • Khon Kaen, Thailand, 40002
        • Research Site
      • Cordaleo, Turkiet (Türkiye), 35575
        • Research Site
      • Istanbul, Turkiet (Türkiye), 34098
        • Research Site
      • Kayseri, Turkiet (Türkiye), 38039
        • Research Site
      • Samsun, Turkiet (Türkiye), 55270
        • Research Site
      • Berlin, Tyskland, 10117
        • Research Site
      • Bochum, Tyskland, 44791
        • Research Site
      • Dresden, Tyskland, 01307
        • Research Site
      • Erlangen, Tyskland, 91054
        • Research Site
      • Essen, Tyskland, 45147
        • Research Site
      • Freiburg im Breisgau, Tyskland, 79104
        • Research Site
      • Hanover, Tyskland, 30625
        • Research Site
      • Kiel, Tyskland, 24105
        • Research Site
      • Leipzig, Tyskland, 04103
        • Research Site
      • Mainz, Tyskland, 55131
        • Research Site
      • Marburg, Tyskland, 35043
        • Research Site
      • Regensburg, Tyskland, 93053
        • Research Site
      • Wuppertal, Tyskland, 42283
        • Research Site
      • Graz, Österrike, 8036
        • Research Site
      • Innsbruck, Österrike, 6020
        • Research Site
      • Linz, Österrike, 4020
        • Research Site
      • Vienna, Österrike, 1130
        • Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Key inclusion criteria:

  • Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:

    • CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
    • Inadequate response or intolerant to antimalarial therapy.
  • Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.

  • Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Key exclusion criteria:

  • History or evidence of suicidal ideation.
  • Severe or life-threatening Systemic lupus erythematosus (SLE).
  • Active SLE or Sjögren's Syndrome.
  • Any active skin conditions other than CLE that may interfere with the study.
  • History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
  • History of recurrent infection requiring hospitalization and IV antibiotics.
  • COVID-19 infection.
  • Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
  • At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Anifrolumab

Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51.

Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

Placebo-jämförare: Placebo

Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.

Matching placebo solution for injection in aPFS.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Tidsram: At Week 24

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

At Week 24

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline in total CLASI-A score
Tidsram: At Week 24

The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE.

At Week 24
Number of participants with CLASI-70 response
Tidsram: At Week 12

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

At Week 12
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Tidsram: At Week 12

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients.

At Week 12
Number of participants with CLASI-50 response
Tidsram: At Week 12 and Week 24

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder.

At Week 12 and Week 24
Number of participants who are sustained CLASI-70 responders
Tidsram: Up to Week 52

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated.

Up to Week 52
Serum trough (pre-dose) concentrations of anifrolumab
Tidsram: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)

The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
Number of participants with positive antidrug antibody
Tidsram: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)

The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
Percent change from baseline in suppression of the Interferon 21-gene
Tidsram: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)

The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
Change from baseline in Skindex-29+3 Symptom domain scores
Tidsram: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life.

At Week 24
Change from baseline in Skindex-29+3 Emotion domain scores
Tidsram: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Function domain scores
Tidsram: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Tidsram: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Total score
Tidsram: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Time from IP start date to CLASI-70 response.
Tidsram: From Week 0/Day 1 up to Week 24

To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

From Week 0/Day 1 up to Week 24
Time from IP start date to CLASI-50 response.
Tidsram: From Week 0/Day 1 up to Week 24

To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

From Week 0/Day 1 up to Week 24

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of participants with adverse events
Tidsram: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE.

Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 juni 2024

Primärt slutförande (Faktisk)

2 november 2026

Avslutad studie (Beräknad)

10 augusti 2027

Studieregistreringsdatum

Först inskickad

1 augusti 2023

Först inskickad som uppfyllde QC-kriterierna

22 augusti 2023

Första postat (Faktisk)

29 augusti 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Tidsram för IPD-delning

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Kriterier för IPD Sharing Access

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera